Industry News
Concerns Mount over Limited Evidence for Accelerated Approvals
January 26th 2022Delays in sponsors providing postapproval evidence of effectiveness for therapies benefitting from streamlined FDA regulatory pathways are generating pressure for further review and reform of the agency’s accelerated approval process.
NICE Recommends Darzalex in Combination with Velcade to Treat Multiple Myeloma
January 14th 2022The UK’s National Institute of Health and Care Excellence has recommended the use of Janssen’s Darzalex (daratumumab) in combination with Velcade (bortezomib), thalidomide and dexamethasone (DVTd) to treat adults with multiple myeloma.